Backed by 25+ years of peer-reviewed research and Nobel Prize-winning science
25 Years of Clinical Validation
1998
Nobel Prize
Nitric Oxide Discovery
Nobel Prize in Medicine awarded for discovering that nitric oxide acts as the body's natural vasodilator, expanding blood vessels to increase circulation.
1999
Clinical Study
First Infrared Wound closure Research
Horwitz, Burke, and Carnegie publish groundbreaking study showing 890nm monochromatic infrared energy accelerates closure of diabetic and venous ulcers.
2004
⭐ Breakthrough
80% Prevention Discovery
Powell, Carnegie, and Burke demonstrate that infrared therapy prevents 80% of diabetic foot wounds by restoring protective sensation. Only 1.5% vs expected 7.3% developed wounds.
2017
Systematic Review
Drug-Free Approach Validated
International systematic review confirms red and near-infrared photobiomodulation as a "promising drug-free approach" for wound closure, with 800-830nm as most-studied range.
2024
Clinical Protocols
Optimized Treatment Guidelines
Dr. Burke provides refined clinical protocols based on decades of experience: optimal duration, frequency, and spacing for maximum closure outcomes.
Published Clinical Research
Research organized by clinical outcomes, evidence synthesis and biological mechanisms
Understanding the Research on Light Therapy
Explore the research on red and near-infrared light therapy for wound care. To help patients and doctors navigate the findings, we’ve grouped the studies into three categories: results from patient studies, reviews that bring together multiple studies, and research into how light may affect the body.
Red and Near-Infrared Photobiomodulation for Diabetic Wounds
A growing body of clinical research has investigated red and near-infrared photobiomodulation (PBM), also known as low-level light or laser therapy (LLLT), for chronic diabetic wounds, particularly diabetic foot ulcers. The studies below examine light therapy alongside conventional wound care or explore physiological responses to treatment.
Patients with diabetes and Grade I–II foot ulcers; home treatment for 12 weeks
Both red and infrared groups showed a tendency toward faster wound healing; infrared LED produced the greatest reduction in ulcer area among the light groups.
23 patients with diabetic foot wounds lasting at least 3 months
After 20 weeks, complete healing was reported in 8 of 13 patients in the laser group versus 3 of 10 receiving placebo; mean healing time was 11 versus 14 weeks.
Mean ulcer area decreased by approximately 63% in the laser group, while the control group's mean ulcer area did not change significantly.
How to interpret this research: These studies used different devices, wavelengths, doses and treatment schedules. Their findings do not establish that Wound Blaster itself heals diabetic wounds or identify a treatment protocol for this device. PBM was investigated as an adjunct, not a replacement for clinician-directed wound care, including infection management, off-loading, dressings and vascular assessment. Study findings should be considered alongside their design limitations and sample sizes.
Tier 1 — Direct Clinical Evidence
These priority studies investigate clinical outcomes in people with diabetic wounds. They provide background for investigating red and near-infrared PBM, rather than proof of the effectiveness of Wound Blaster itself. Use the wavelength groups above to navigate the individual trials. Torkaman’s wound-area results belong here; its biomarker findings are considered separately in Tier 3.
Research settings, not treatment instructions: Wavelengths, energy densities and schedules below describe research protocols. They are not recommendations for self-treatment or a validated Wound Blaster protocol. Diabetic wounds require clinician-directed care. Devices, study populations and outcomes differ, and preliminary or mechanistic findings should not be treated as established clinical benefits.
2024Randomized Trial
904 nm — Cardoso et al., 2024: PBM for Diabetic Foot Ulcers
A randomized, double-blind, placebo-controlled trial involved 80 people with non-infected diabetic foot ulcers. Researchers compared 904-nm photobiomodulation at 4, 8 and 10 J/cm² with a placebo/control, alongside conventional wound care.
Reported finding
The study reported reduced ulcer size with PBM and 60% complete healing in the 10 J/cm² group. This result applies to that study group and protocol, not to all PBM devices or patients.
Research relevance: This is direct human clinical evidence involving infrared PBM and diabetic foot ulcers, rather than an inference from cell or animal studies. It is an important starting point for reviewing the modality, while device-specific evidence is still needed.
850 nm with Red Light — LED Phototherapy for Chronic Diabetic Wounds, 2018
Phototherapy with LED Shows Promising Results in Healing Chronic Wounds in Diabetes Mellitus Patients examined 60 patients using a light system incorporating 625, 660 and 850 nm.
Energy density: 2.4 J/cm².
Schedule: three treatments per week for eight weeks.
Comparator: simulated-light control.
Reported finding
The researchers reported significantly faster wound-bed healing with LED treatment than with simulated light.
Research relevance: This study includes an 850-nm near-infrared LED alongside red wavelengths, making it useful when reviewing LED-based approaches. A combined-wavelength study does not isolate the effect of 850 nm or establish equivalence to Wound Blaster.
808 nm — At-Home PBM for Severe Diabetic Foot Ulcers
A randomized, double-blind, sham-controlled pilot study evaluated at-home photobiomodulation laser therapy in people with severe diabetic foot ulcers and significant coexisting conditions. Participants continued standard wound care. The study used 808-nm pulsed near-infrared light at 8.8 J/cm².
Reported endpoint findings
PBM group: median wound area decreased from 20.3 cm² to 0.2 cm².
Sham group: median wound area decreased from 7.9 cm² to 4.6 cm².
More than 90% wound closure occurred in 7 of 10 PBM patients and 1 of 10 sham patients.
No adverse device effects were observed in this small study.
Research relevance and limitations: This offers a precedent for investigating home-based PBM, rather than only clinic-administered treatment. The authors described the results as preliminary and recommended a larger trial. The small sample and differing starting wound areas matter; absence of observed adverse effects does not establish general safety.
904 nm — Torkaman et al., 2024: Clinical Outcomes and Vascular Signaling
A double-blind randomized trial involved 30 patients with Grade II diabetic foot ulcers. Both groups received standard wound care. The reported PBM protocol used 904 nm at 2 J/cm², three days per week over four weeks, with 11 sessions.
The investigators examined HIF-1α, VEGF, VEGFR-2, nitric oxide and wound surface-area reduction—measures relevant to oxygen-response pathways, angiogenesis and wound healing.
Reported finding
The PBM group had significantly greater wound-area reduction. The study also investigated biological pathways that may help explain treatment responses.
Research relevance: These findings can inform a scientific rationale for studying PBM. Changes in biomarkers must not be turned into claims that Wound Blaster improves circulation, oxygenation or healing.
The trial studied red and infrared LED treatment groups in patients with Grade I–II diabetic foot ulcers, with home treatment over 12 weeks.
Reported finding
Both light groups showed a tendency toward faster wound healing. Infrared LED produced the greatest reduction in ulcer area among the light groups.
Research relevance: This is human clinical evidence involving home-based LED treatment. The findings relate to the studied devices and protocols, not a demonstrated benefit of Wound Blaster. Red and infrared treatment groups should not be confused with a single combined-wavelength treatment.
Reviews place the individual studies in context. Consider their search methods, included study designs, sample sizes and limitations; systematic reviews and narrative reviews do not provide the same type of synthesis.
This review included 28 randomized studies involving 1,471 patients and examined red and infrared light as adjuncts to conventional diabetic foot ulcer care.
Reported pooled findings
Higher ulcer-healing rate: relative risk 1.93.
Shorter healing time: approximately 18.5 days on average.
No statistically significant difference in adverse events between treatment and control groups.
Evidence limitations: The authors noted limitations in study quality and sample size and called for additional high-quality research. Pooled estimates are not predictions for an individual patient or proof of a specific device's performance. A non-significant adverse-event difference is not proof that risks are absent.
LED Systematic Review — Tissue Repair in Chronic Diabetic Wounds
Baracho and colleagues' systematic review selected eight articles evaluating LED phototherapy in chronic wounds in people with diabetes, including randomized and observational clinical studies.
Review conclusions
The review described evidence suggesting benefits involving tissue repair, collagen production, fibroblasts, angiogenesis, reduced inflammation and smaller lesions.
Research relevance and limitations: LED-specific literature adds context beyond laser studies alone. Results were not uniform, treatment parameters varied, and some studies had small samples or other methodological limitations. The review supports further research rather than a universal treatment protocol.
2021 Review — Diabetic Foot and Lower-Leg Ulcer Healing
Sutton and colleagues' review examined 13 studies involving 417 participants. Wavelengths associated with favorable healing outcomes included red light at 630 and 660 nm and near-infrared light at 850 and 890 nm.
Commonly favorable radiant exposures were reported in the approximate range of 3–7 J/cm², but the protocols varied substantially.
How to interpret the range
These studies do not establish one universally correct wavelength, dose or treatment schedule. Their findings must be considered with the light source, delivery method, wound characteristics and conventional care used in each study.
Red and Near-Infrared PBM in Diabetic Wound Healing
Photobiomodulation in diabetic wound healing: A review of red and near-infrared wavelength applications.
This reference complements the LED-specific and foot/lower-leg ulcer reviews in the evidence synthesis. Its scope concerns red and near-infrared applications; it is not a Wound Blaster clinical trial.
Review note: The full text was not available for verification here. Consult the original paper for its methods, findings and limitations before using it in a clinical or regulatory submission.
Keep biological pathways, tissue measurements and proposed mechanisms separate from clinical healing outcomes. These topics help frame research questions; listing them does not mean that every pathway has been demonstrated in humans or with Wound Blaster.
Nitric oxide
Document measured nitric oxide findings separately from claims about circulation or healing. The Torkaman trial includes nitric oxide among its investigated markers.
VEGF
Record VEGF and VEGFR-2 findings as vascular-signaling markers. A biomarker change is not itself evidence of wound closure.
Angiogenesis
Distinguish proposed blood-vessel formation pathways from directly measured vascular changes and clinical outcomes.
Mitochondrial activity
Document cellular-energy hypotheses with their source and experimental model; do not extrapolate cellular findings directly to patient benefit.
Fibroblast activity
Keep cell-level repair findings separate from wound-area reduction and complete healing in patients.
Collagen
Distinguish collagen-production or remodeling measurements from clinical healing endpoints.
Inflammation
Identify the specific inflammatory markers, tissue and study design rather than implying a general anti-inflammatory benefit.
Microcirculation
Record vascular or blood-flow measurements as physiological endpoints, not substitutes for clinical wound outcomes.
Oxygenation
Separate oxygen-response biomarkers and spectroscopy measurements from demonstrated tissue oxygen delivery or healing.
Evidence documentation: For each mechanism, record the source, human/animal/cell model, measured endpoint and limitations. The Torkaman trial informs the vascular-signaling discussion; the LED review provides context on repair-related mechanisms. Neither proves all of the mechanisms listed above or establishes a Wound Blaster clinical benefit.
Physiological Evidence
Near-Infrared Spectroscopy — Physiological Responses, Not Healing Outcomes
This study used near-infrared spectroscopy to examine responses to low-level light therapy in 45 patients with diabetic foot ulcers, plus healthy controls. Researchers monitored total hemoglobin concentration and vascular or nervous-system responses following treatment.
Measurement is different from treatment
Near-infrared spectroscopy measures tissue responses. It should not be confused with near-infrared PBM used as treatment, and physiological changes alone do not establish wound healing.
Research relevance: This work can inform the rationale for investigating light therapy and possible mechanisms, while remaining separate from clinical healing outcomes.
Earlier clinical reports, reviews, industry commentary and modeling provide context beyond the priority studies above. Their evidence types and limitations should be assessed separately.
1999Peer-Reviewed
Augmentation of Wound closure Using Monochromatic Infrared Energy
L.R. Horwitz, T.J. Burke, D. Carnegie
Advances in Wound Care, Jan-Feb 1999
Key Finding
890nm monochromatic infrared energy successfully treats diabetic ulcers, venous ulcers, and scleroderma-related wounds that failed conventional treatment. closure mechanism linked to local nitric oxide increases.
Reversal of Diabetic Peripheral Neuropathy and New Wound Incidence
Mark W. Powell, Dale E. Carnegie, Thomas J. Burke
Advanced Skin & Wound Care, July-Aug 2004
Key Finding
Dramatic 80% reduction in new diabetic foot wounds. Only 1 of 68 high-risk patients (1.5%) developed new wounds vs. expected 7.3%, proving infrared therapy prevents wounds by restoring protective sensation.
Red and Near-Infrared Photobiomodulation for Impaired Wound closure
Anju Yadav, Asheesh Gupta
Photodermatol Photoimmunol Photomed, Jan 2017
Key Finding
Systematic review confirms photobiomodulation as "promising drug-free approach" for wound closure. Near-infrared wavelengths (800-830nm) identified as most-studied and effective range.
Wavelength and Beam Width Effects on Light Penetration
Caerwyn Ash, Michael Dubec, Kelvin Donne, Tim Bashford
Lasers in Medical Science, Sep 2017
Key Finding
Monte Carlo modeling confirms near-infrared wavelengths achieve maximum tissue penetration (5.4mm), validating 890nm as optimal for reaching deep tissue and blood vessels.
